BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923-928. [PMID: 19303163 DOI: 10.1016/j.jhep.2009.01.014] [Cited by in Crossref: 228] [Cited by in F6Publishing: 193] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Wan S, Wei Y, Zhang X, Yang C, Hu F, Song B. Computed Tomography-Based Texture Features for the Risk Stratification of Portal Hypertension and Prediction of Survival in Patients With Cirrhosis: A Preliminary Study. Front Med 2022;9:863596. [DOI: 10.3389/fmed.2022.863596] [Reference Citation Analysis]
2 Choi AY, Chang KJ, Samarasena JB, Lee JG, Li X, Guo W, Chandan VS, Hu K. Endoscopic Ultrasound-Guided Porto-systemic Pressure Gradient Measurement Correlates with Histological Hepatic Fibrosis. Dig Dis Sci. [DOI: 10.1007/s10620-022-07418-7] [Reference Citation Analysis]
3 Thalheimer U, Bellis L, Puoti C, Burroughs AK. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No. Eur J Intern Med 2011;22:5-7. [PMID: 21238884 DOI: 10.1016/j.ejim.2010.12.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
4 Stefanescu H, Procopet B. Noninvasive assessment of portal hypertension in cirrhosis: Liver stiffness and beyond. World J Gastroenterol 2014; 20(45): 16811-16819 [PMID: 25492995 DOI: 10.3748/wjg.v20.i45.16811] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
5 Bang CS, Kim HS, Suk KT, Kim SE, Park JW, Park SH, Kim HS, Jang MK, Park SH, Lee MS, Park CK, Kim DJ. Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis. BMC Gastroenterol 2016;16:93. [PMID: 27519178 DOI: 10.1186/s12876-016-0508-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
7 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
8 Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140:840-889; quiz e12. [PMID: 21129375 DOI: 10.1053/j.gastro.2010.11.050] [Cited by in Crossref: 136] [Cited by in F6Publishing: 132] [Article Influence: 11.3] [Reference Citation Analysis]
9 Al-Hamoudi WK. Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi J Gastroenterol. 2010;16:145-153. [PMID: 20616408 DOI: 10.4103/1319-3767.65181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
10 Donahue LA, Kulik L, Baker T, Ganger DR, Gupta R, Memon K, Abecassis MM, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013;24:74-80. [PMID: 23273699 DOI: 10.1016/j.jvir.2012.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
11 Tanaka T, Hirooka M, Koizumi Y, Watanabe T, Yoshida O, Tokumoto Y, Nakamura Y, Sunago K, Yukimoto A, Abe M, Hiasa Y. Development of a method for measuring spleen stiffness by transient elastography using a new device and ultrasound-fusion method. PLoS One 2021;16:e0246315. [PMID: 33539456 DOI: 10.1371/journal.pone.0246315] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Persico M, Bruno S, Costantino A, Mazza M, Almasio PL. The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol 2011;2011:314301. [PMID: 22164334 DOI: 10.4061/2011/314301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Simbrunner B, Marculescu R, Scheiner B, Schwabl P, Bucsics T, Stadlmann A, Bauer DJM, Paternostro R, Eigenbauer E, Pinter M, Stättermayer AF, Trauner M, Mandorfer M, Reiberger T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int 2020;40:1713-24. [PMID: 32358998 DOI: 10.1111/liv.14498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Abraldes JG, Sarlieve P, Tandon P. Measurement of portal pressure. Clin Liver Dis. 2014;18:779-792. [PMID: 25438283 DOI: 10.1016/j.cld.2014.07.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
15 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
16 Tarantino G, Citro V, Conca P, Riccio A, Tarantino M, Capone D, Cirillo M, Lobello R, Iaccarino V. What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? BMC Gastroenterol. 2009;9:89. [PMID: 19930687 DOI: 10.1186/1471-230x-9-89] [Cited by in Crossref: 64] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
17 Kim NH, Lee T, Cho YK, Kim BI, Kim HJ. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization: Clinically evident portal hypertension. Journal of Gastroenterology and Hepatology 2018;33:1397-406. [DOI: 10.1111/jgh.14083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int 2018;38:821-33. [PMID: 28941023 DOI: 10.1111/liv.13596] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
19 Grace ND. Patients With Clinically Significant Portal Hypertension Caused by Hepatitis C Virus Cirrhosis Respond Poorly to Antiviral Therapy. Clinical Gastroenterology and Hepatology 2011;9:536-8. [DOI: 10.1016/j.cgh.2011.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692-9. [PMID: 27242316 DOI: 10.1016/j.jhep.2016.05.027] [Cited by in Crossref: 165] [Cited by in F6Publishing: 151] [Article Influence: 27.5] [Reference Citation Analysis]
21 Mohanty A. Peptide-based therapy in portal hypertension. Curr Opin Endocrinol Diabetes Obes 2020;27:22-7. [PMID: 31815783 DOI: 10.1097/MED.0000000000000528] [Reference Citation Analysis]
22 Jain D, Sreenivasan P, Inayat I, Deng Y, Ciarleglio MM, Garcia-Tsao G. Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis. Am J Clin Pathol 2021:aqab024. [PMID: 33940622 DOI: 10.1093/ajcp/aqab024] [Reference Citation Analysis]
23 Piñero F, Vazquez M, Baré P, Rohr C, Mendizabal M, Sciara M, Alonso C, Fay F, Silva M. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. Ann Hepatol 2019;18:480-7. [PMID: 31023615 DOI: 10.1016/j.aohep.2018.10.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
24 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
25 Suk KT, Kim CH, Park SH, Sung HT, Choi JY, Han KH, Hong SH, Kim DY, Yoon JH, Kim YS. Comparison of hepatic venous pressure gradient and two models of end-stage liver disease for predicting the survival in patients with decompensated liver cirrhosis. J Clin Gastroenterol. 2012;46:880-886. [PMID: 22810110 DOI: 10.1097/mcg.0b013e31825f2622] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
26 Gifford FJ, Dunne PDJ, Weir G, Ireland H, Graham C, Tuck S, Hayes PC, Fallowfield JA. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials 2020;21:260. [PMID: 32164767 DOI: 10.1186/s13063-020-4203-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 DeWitt JM, Arain M, Chang KJ, Sharaiha R, Komanduri S, Muthusamy VR, Hwang JH;  AGA Center for GI Innovation and Technology. Interventional Endoscopic Ultrasound: Current Status and Future Directions. Clin Gastroenterol Hepatol. 2021;19:24-40. [PMID: 32950747 DOI: 10.1016/j.cgh.2020.09.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
28 Kim R, Jeong WK, Kang TW, Song KD, Lee MW, Ahn SH, Rhim H. Intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma: relationship with portal hypertension. Acta Radiol 2019;60:1609-18. [DOI: 10.1177/0284185119842830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Christensen E. Portal hypertension and development of hepatocellular carcinoma: factors influencing significance in prognostic models. J Hepatol 2009;50:848-9. [PMID: 19299028 DOI: 10.1016/j.jhep.2009.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Dercle L, Billey C, Cognet T, Cassol E, Sinigaglia M, Pascal P, Berry I, Otal P, Bureau C, Lairez O. Spleno-hepatic index to predict portal hypertension by equilibrium radionuclide ventriculography. Nucl Med Commun 2018;39:1138-42. [PMID: 30371604 DOI: 10.1097/MNM.0000000000000927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Shao R, Li Z, Wang J, Qi R, Liu Q, Zhang W, Mao X, Song X, Li L, Liu Y, Zhao X, Liu C, Li X, Zuo C, Wang W, Qi X. Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial devascularisation versus endoscopic therapy for secondary prophylaxis for variceal rebleeding in portal hypertension (CHESS1803): study protocol of a multicenter randomised controlled trial in China. BMJ Open 2020;10:e030960. [PMID: 32580978 DOI: 10.1136/bmjopen-2019-030960] [Reference Citation Analysis]
32 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310-335. [PMID: 27786365 DOI: 10.1002/hep.28906] [Cited by in Crossref: 713] [Cited by in F6Publishing: 537] [Article Influence: 118.8] [Reference Citation Analysis]
33 Forns X, Bruix J. Treating hepatitis C in patients with cirrhosis: The effort is worth it. Journal of Hepatology 2010;52:624-6. [DOI: 10.1016/j.jhep.2010.01.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
34 Bosch J. Soft technique, hard end-points. Journal of Hepatology 2011;55:955-6. [DOI: 10.1016/j.jhep.2011.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 Dajti E, Marasco G, Ravaioli F, Alemanni LV, Rossini B, Colecchia L, Vestito A, Festi D, Colecchia A. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterol (Torino) 2021;67:151-63. [PMID: 34027932 DOI: 10.23736/S2724-5985.20.02793-2] [Reference Citation Analysis]
36 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
37 Jansen C, Bogs C, Verlinden W, Thiele M, Möller P, Görtzen J, Lehmann J, Vanwolleghem T, Vonghia L, Praktiknjo M, Chang J, Krag A, Strassburg CP, Francque S, Trebicka J. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. Liver Int 2017;37:396-405. [DOI: 10.1111/liv.13243] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 12.3] [Reference Citation Analysis]
38 Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, Blasco H, Procopet B, Tsochatzis E, Westbrook RH, Bosch J, Berzigotti A, Abraldes JG, Genescà J. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease: Augustin, Pons, et al. Hepatology 2017;66:1980-8. [DOI: 10.1002/hep.29363] [Cited by in Crossref: 129] [Cited by in F6Publishing: 100] [Article Influence: 25.8] [Reference Citation Analysis]
39 Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24:823-831. [PMID: 28295923 DOI: 10.1111/jvh.12706] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 14.2] [Reference Citation Analysis]
40 Ma C, Brunt EM. Histopathologic Evaluation of Liver Biopsy for Cirrhosis. Advances in Anatomic Pathology 2012;19:220-30. [DOI: 10.1097/pap.0b013e31825c6bab] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
41 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
42 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
43 Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9(5): 270-277 [PMID: 28261384 DOI: 10.4254/wjh.v9.i5.270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
44 Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51:2214-2218. [PMID: 20513005 DOI: 10.1002/hep.23689] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
45 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405. [PMID: 25557690 DOI: 10.1002/hep.27678] [Cited by in Crossref: 213] [Cited by in F6Publishing: 194] [Article Influence: 30.4] [Reference Citation Analysis]
46 Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Suzuki E, Ooka Y, Chiba T, Yamaguchi T. Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. Int J Med Sci 2017;14:804-10. [PMID: 28824317 DOI: 10.7150/ijms.19847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P. Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2021:S0168-8278(21)02043-2. [PMID: 34592366 DOI: 10.1016/j.jhep.2021.09.013] [Reference Citation Analysis]
48 Corma-gómez A, Macías J, Téllez F, Freyre-carrillo C, Morano L, Rivero-juárez A, Ríos MJ, Alados JC, Vera-méndez FJ, Merchante N, Palacios R, Granados R, Merino D, De Los Santos I, Pineda JA. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clinical Infectious Diseases 2019. [DOI: 10.1093/cid/ciz1140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
49 Zhou H, Hu H, Tian M, Chu J, Tian C, Yang Y, Lin S. Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices. Gastroenterol Res Pract 2020;2020:4217512. [PMID: 33376483 DOI: 10.1155/2020/4217512] [Reference Citation Analysis]
50 Bosch J, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, de la Peña J, Escorsell A, García-pagán JC, Genescà J, Hernández-guerra M, Ripoll C, Planas R, Villanueva C. Hipertensión portal: recomendaciones para su evaluación y tratamiento. Gastroenterología y Hepatología 2012;35:421-50. [DOI: 10.1016/j.gastrohep.2012.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
51 Singal AK, Jampana SC, Singal V, Kuo YF. Hepatocellular carcinoma predicts in-hospital mortality from acute variceal hemorrhage among patients with cirrhosis. J Clin Gastroenterol. 2012;46:613-619. [PMID: 22772741 DOI: 10.1097/mcg.0b013e318256b670] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
52 Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World J Gastroenterol 2013; 19(8): 1193-1199 [PMID: 23482437 DOI: 10.3748/wjg.v19.i8.1193] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
53 Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15:308. [PMID: 23314828 DOI: 10.1007/s11894-012-0308-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
54 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
55 Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, Andreani S, Vandelli G, Bernabucci V, Lei B, D'Ambrosio F, Bristot L, Cavalletto L, Chemello L, Sighinolfi P, Manni P, Maiorana A, Caporali C, Bianchini M, Marsico M, Turco L, de Maria N, Del Buono M, Todesca P, di Lena L, Romagnoli D, Magistri P, di Benedetto F, Bruno S, Taliani G, Giannelli G, Martinez-Chantar ML, Villa E. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology. 2018;68:1010-1024. [PMID: 29604220 DOI: 10.1002/hep.29911] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 21.0] [Reference Citation Analysis]
56 Strazzabosco M. Toward a rational management of very early hepatocellular carcinoma. Hepatology 2013;57:1300-2. [PMID: 22987787 DOI: 10.1002/hep.26074] [Reference Citation Analysis]
57 Perez-latorre L, Sanchez-conde M, Rincon D, Miralles P, Aldamiz-echevarria T, Carrero A, Tejerina F, Diez C, Bellon JM, Banares R, Berenguer J. Prediction of Liver Complications in Patients With Hepatitis C Virus-Related Cirrhosis With and Without HIV Coinfection: Comparison of Hepatic Venous Pressure Gradient and Transient Elastography. Clinical Infectious Diseases 2014;58:713-8. [DOI: 10.1093/cid/cit768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
58 Sidali S, Nault JC. Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters. United European Gastroenterol J 2022. [PMID: 34997990 DOI: 10.1002/ueg2.12193] [Reference Citation Analysis]
59 Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. Expert Rev Gastroenterol Hepatol 2018;12:155-64. [PMID: 28856972 DOI: 10.1080/17474124.2017.1374852] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
60 Zykus R, Jonaitis L, Petrenkienė V, Pranculis A, Kupčinskas L. Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease: a prospective cohort study. BMC Gastroenterol 2015;15:183. [PMID: 26702818 DOI: 10.1186/s12876-015-0414-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
61 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
62 Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf). 2017;5:79-89. [PMID: 28533906 DOI: 10.1093/gastro/gox012] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 12.4] [Reference Citation Analysis]
63 Qi X, Zhang X, Li Z, Hui J, Xiang Y, Chen J, Zhao J, Li J, Qi FZ, Xu Y. HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. Oncotarget 2016;7:62789-96. [PMID: 27566593 DOI: 10.18632/oncotarget.11558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
64 Colecchia A, Marasco G, Taddia M, Montrone L, Eusebi LH, Mandolesi D, Schiumerini R, Di Biase AR, Festi D. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature. European Journal of Gastroenterology & Hepatology 2015;27:992-1001. [DOI: 10.1097/meg.0000000000000393] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
65 Sethasine S, Jain D, Groszmann RJ, Garcia-Tsao G. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology 2012;55:1146-53. [PMID: 22109744 DOI: 10.1002/hep.24805] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
66 Nowicki TK, Markiet K, Szurowska E. Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. Curr Med Imaging Rev 2017;13:140-53. [PMID: 28553196 DOI: 10.2174/1573405612666160720123748] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
67 Wani ZA, Baht RA, Bhadoria AS, Maiwall R, Majeed Y, Khan AA, Zargar SA, Shah MA, Khan KM. After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis? Saudi J Gastroenterol. 2015;21:278-283. [PMID: 26458853 DOI: 10.4103/1319-3767.164207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget 2017;8:92431-41. [PMID: 29190928 DOI: 10.18632/oncotarget.21369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
69 Pinato DJ, Karamanakos G, Ishizuka M, Smirne C, Pirisi M, Kubota K, Sharma R. The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. Liver Int 2015;35:2458-65. [PMID: 25845291 DOI: 10.1111/liv.12841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
70 Abe H, Midorikawa Y, Okada M, Takayama T. Clinical application of magnetic resonance elastography in chronic liver disease: Performance of MRE in CLD. Hepatol Res 2018;48:780-7. [DOI: 10.1111/hepr.13231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
71 Karagiannakis DS, Voulgaris T, Siakavellas SI, Papatheodoridis GV, Vlachogiannakos J. Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. Scand J Gastroenterol 2018;53:1153-64. [PMID: 30345856 DOI: 10.1080/00365521.2018.1506046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
72 Schwarzer R, Reiberger T, Mandorfer M, Kivaranovic D, Hametner S, Hametner S, Paternostro R, Scheiner B, Schneeweiss-Friedl J, Trauner M, Schoefl R, Maieron A. The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. J Gastroenterol 2020;55:533-42. [PMID: 31832759 DOI: 10.1007/s00535-019-01656-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
73 Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol 2021;18:117-35. [PMID: 32999450 DOI: 10.1038/s41569-020-0433-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
74 Zhou LL, Wang GC, Zhang MY, Huang GJ, Li W, Wang LY, Wang AH, Zhang CQ. Nomogram for hepatic venous pressure gradient in patients with cirrhosis. J Dig Dis 2021;22:488-95. [PMID: 34272920 DOI: 10.1111/1751-2980.13033] [Reference Citation Analysis]
75 Shao R, Liu C, Liu Y, Mao H, Li X, Qi X. Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial". Ann Surg 2021;274:e194-5. [PMID: 31714312 DOI: 10.1097/SLA.0000000000003679] [Reference Citation Analysis]
76 Souto EO. Endoscopic Ultrasound Evaluation of Portal Pressure. Clin Liver Dis 2022;26:e1-e10. [PMID: 34802666 DOI: 10.1016/j.cld.2021.10.001] [Reference Citation Analysis]
77 Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol 2012; 18(11): 1166-1175 [PMID: 22468079 DOI: 10.3748/wjg.v18.i11.1166] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 70] [Article Influence: 8.1] [Reference Citation Analysis]
78 Lee E, Kim YJ, Goo DE, Yang SB, Kim HJ, Jang JY, Jeong SW. Comparison of hepatic venous pressure gradient and endoscopic grading of esophageal varices. World J Gastroenterol 2016; 22(11): 3212-3219 [PMID: 27003998 DOI: 10.3748/wjg.v22.i11.3212] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
79 Dajti E, Marasco G, Ravaioli F, Colecchia L, Ferrarese A, Festi D, Colecchia A. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. JHEP Rep 2021;3:100289. [PMID: 34095798 DOI: 10.1016/j.jhepr.2021.100289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Nakatsuka T, Tateishi R, Nakagomi R, Minami T, Koike K. Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.002] [Reference Citation Analysis]
81 Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J Hepatol 2015; 7(3): 607-615 [PMID: 25848485 DOI: 10.4254/wjh.v7.i3.607] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
82 Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. Journal of Hepatology 2015;63:1118-25. [DOI: 10.1016/j.jhep.2015.06.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
83 Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol 2014;13:386-93. [PMID: 24927609 [PMID: 24927609 DOI: 10.1016/s1665-2681(19)30845-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
84 Miñano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am 2010;39:681-95. [PMID: 20951924 DOI: 10.1016/j.gtc.2010.08.015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
85 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 395] [Article Influence: 100.1] [Reference Citation Analysis]
86 Hagan M, Asrani SK, Talwalkar J. Non-invasive assessment of liver fibrosis and prognosis. Expert Review of Gastroenterology & Hepatology 2015;9:1251-60. [DOI: 10.1586/17474124.2015.1075391] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
87 Song J, Huang J, Huang H, Liu S, Luo Y. Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension: A meta-analysis. Clin Res Hepatol Gastroenterol. 2018;42:216-226. [PMID: 29223365 DOI: 10.1016/j.clinre.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
88 Suk KT. Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol. 2014;20:6-14. [PMID: 24757653 DOI: 10.3350/cmh.2014. 20.1.6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Reference Citation Analysis]
90 Hüsing-Kabar A, Meister T, Köhler M, Domschke W, Kabar I, Wilms C, Hild B, Schmidt HH, Heinzow HS. Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased? United European Gastroenterol J 2018;6:413-21. [PMID: 29774155 DOI: 10.1177/2050640617732886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
92 Merkel C, Montagnese S. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes! Eur J Intern Med 2011;22:1-4. [PMID: 21238883 DOI: 10.1016/j.ejim.2010.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
93 Koh C, Heller T. Approach to the diagnosis of portal hypertension. Clin Liver Dis (Hoboken) 2012;1:133-5. [PMID: 31186871 DOI: 10.1002/cld.78] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
94 Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology & Hepatology 2015;9:603-27. [DOI: 10.1586/17474124.2015.1007955] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
95 Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol. 2017;67:399-411. [PMID: 28223101 DOI: 10.1016/j.jhep.2017.02.003] [Cited by in Crossref: 110] [Cited by in F6Publishing: 96] [Article Influence: 22.0] [Reference Citation Analysis]
96 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
97 Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7:141-155. [PMID: 23363263 DOI: 10.1586/egh.12.83] [Cited by in Crossref: 144] [Cited by in F6Publishing: 107] [Article Influence: 16.0] [Reference Citation Analysis]
98 Ripoll C, Lastra P, Rincón D, Catalina V, Bañares R. Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. Scand J Gastroenterol 2012;47:204-11. [PMID: 22242615 DOI: 10.3109/00365521.2011.645500] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
99 Silva-Junior G, Baiges A, Turon F, Torres F, Hernández-Gea V, Bosch J, García-Pagán JC. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology 2015;62:1584-92. [PMID: 26238376 DOI: 10.1002/hep.28031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
100 Gouya H, Grabar S, Vignaux O, Saade A, Pol S, Legmann P, Sogni P. Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging. Eur Radiol 2016;26:1981-90. [DOI: 10.1007/s00330-015-3991-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
101 An C, Choi JW, Lee HS, Lim H, Ryu SJ, Chang JH, Oh HC. Prediction of the risk of developing hepatocellular carcinoma in health screening examinees: a Korean cohort study. BMC Cancer 2021;21:755. [PMID: 34187409 DOI: 10.1186/s12885-021-08498-w] [Reference Citation Analysis]
102 Wang HY, Song QK, Yue ZD, Wang L, Fan ZH, Wu YF, Dong CB, Zhang Y, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ. Correlation of pressure gradient in three hepatic veins with portal pressure gradient. World J Clin Cases 2022; 10(14): 4460-4469 [DOI: 10.12998/wjcc.v10.i14.4460] [Reference Citation Analysis]
103 Merkel C, Montagnese S. Hepatic venous pressure gradient measurement in clinical hepatology. Dig Liver Dis 2011;43:762-7. [PMID: 21549649 DOI: 10.1016/j.dld.2011.03.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
104 Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32:1407-1414. [PMID: 22679906 DOI: 10.1111/j.1478-3231.2012.02830.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 105] [Article Influence: 13.8] [Reference Citation Analysis]
105 Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1654-1664. [PMID: 22849701 DOI: 10.1111/j.1440-1746.2012.07232.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
106 de Oliveira AC. Short article: Noninvasive assessment of portal hypertension and detection of esophageal varices in cirrhosis. European Journal of Gastroenterology & Hepatology 2017;29:531-4. [DOI: 10.1097/meg.0000000000000830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
107 Gordon AC, Gupta AN, Gabr A, Thornburg BG, Kulik LM, Ganger DR, Maddur H, Flamm SL, Boike JR, Moore CM, Borja-Cacho D, Christopher DA, Katariya NN, Ladner DP, Caicedo-Ramirez JC, Riaz A, Salem R, Lewandowski RJ. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol 2021;32:211-9. [PMID: 33349507 DOI: 10.1016/j.jvir.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Trebicka J, Reiberger T, Laleman W. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. Visc Med. 2018;34:270-275. [PMID: 30345284 DOI: 10.1159/000490262] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
109 Renzulli M, Dajti E, Ierardi AM, Brandi N, Berzigotti A, Milandri M, Rossini B, Clemente A, Ravaioli F, Marasco G, Azzaroli F, Carrafiello G, Festi D, Colecchia A, Golfieri R. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. Eur J Radiol 2021;:110010. [PMID: 34801322 DOI: 10.1016/j.ejrad.2021.110010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis. 2010;42 Suppl 3:S215-S222. [PMID: 20547306 DOI: 10.1016/s1590-8658(10)60508-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
111 Jindal A, Bhardwaj A, Kumar G, Sarin SK. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg. Am J Gastroenterol 2020;115:1624-33. [PMID: 32453061 DOI: 10.14309/ajg.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
112 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
113 Abraldes JG, Araujo IK, Turón F, Berzigotti A. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol. 2012;35:488-495. [PMID: 22560536 DOI: 10.1016/j.gastrohep.2012.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
114 Maurice J, Pinzani M. The stratification of cirrhosis. Hepatol Res 2020;50:535-41. [PMID: 32072721 DOI: 10.1111/hepr.13493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
115 Thiele M, Wiest R, Gluud LL, Albillos A, Krag A. Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses. 2013;81:871-874. [PMID: 24060485 DOI: 10.1016/j.mehy.2013.08.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
116 Wei G, Cao J, Huang P, An P, Badlani D, Vaid KA, Zhao S, Wang DQ, Zhuo J, Yin L, Frassetto A, Markel A, Presnyak V, Gandham S, Hua S, Lukacs C, Finn PF, Giangrande PH, Martini PGV, Popov YV. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3. J Hepatol 2021;74:1416-28. [PMID: 33340584 DOI: 10.1016/j.jhep.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 La Mura V, Garcia‐guix M, Berzigotti A, Abraldes JG, García‐pagán JC, Villanueva C, Bosch J. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology 2020;72:1353-65. [DOI: 10.1002/hep.31125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
118 Liu C, Shao R, Wang S, Wang G, Wang L, Zhang M, Liu Y, Liang M, Li X, Kang N, Wang J, Xu D, Mao H, Zhang C, Qi X. The Presence of Ascites Affects the Predictive Value of HVPG on Early Rebleeding in Patients with Cirrhosis. Gastroenterol Res Pract 2020;2020:1329857. [PMID: 33299405 DOI: 10.1155/2020/1329857] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Sinagra E, Perricone G, D’Amico M, Tinè F, D’Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39:557-568. [PMID: 24461301 DOI: 10.1111/apt.12634] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
120 Xu G, Li F, Mao Y. Portal pressure monitoring-state-of-the-art and future perspective. Ann Transl Med. 2019;7:583. [PMID: 31807564 DOI: 10.21037/atm.2019.09.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
121 Vorobioff J, Groszmann R. Portal Hypertension—Molecular Mechanisms. Liver Pathophysiology. Elsevier; 2017. pp. 435-49. [DOI: 10.1016/b978-0-12-804274-8.00034-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Vincent JK, Stark C, Shields JT, Bhave AD, Morris CS. Hepatic venous pressure gradient correlates with advanced hepatic fibrosis: a retrospective review. Abdom Radiol (NY) 2017;42:2609-14. [PMID: 28474176 DOI: 10.1007/s00261-017-1171-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Bruno S, Boccaccio V, Russo ML, Maisonneuve P. Is the benefit of treating patients with cirrhosis proven? Liver Int. 2016;36 Suppl 1:21-27. [PMID: 26725893 DOI: 10.1111/liv.13013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
124 Herrera I, Pascual S, Zapater P, Carnicer F, Bellot P, María Palazón J. The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis. Eur J Gastroenterol Hepatol 2016;28:1194-7. [PMID: 27294486 DOI: 10.1097/MEG.0000000000000677] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
125 Garcia-Tsao G, Bosch J. Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol. 2015;13:2109-2117. [PMID: 26192141 DOI: 10.1016/j.cgh.2015.07.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 6.1] [Reference Citation Analysis]
126 Lens S, Baiges A, Alvarado-tapias E, Llop E, Martinez J, Fortea JI, Ibáñez-samaniego L, Mariño Z, Rodríguez-tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-gea V, Bosch J, Villanueva C, García-pagán JC, Forns X. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology 2020;73:1415-24. [DOI: 10.1016/j.jhep.2020.05.050] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
127 Asesio N, Pollo-Flores P, Caliez O, Munteanu M, Ngo A, Ngo Y, Poynard T, Thabut D, Rudler M. Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. Dig Liver Dis 2021:S1590-8658(21)00773-8. [PMID: 34583904 DOI: 10.1016/j.dld.2021.09.004] [Reference Citation Analysis]
128 Talakić E, Schaffellner S, Kniepeiss D, Mueller H, Stauber R, Quehenberger F, Schoellnast H. CT perfusion imaging of the liver and the spleen in patients with cirrhosis: Is there a correlation between perfusion and portal venous hypertension? Eur Radiol 2017;27:4173-80. [PMID: 28321540 DOI: 10.1007/s00330-017-4788-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
129 Kristensen H, Kimer N, Møller S. Indications and methods for measuring portal hypertension in cirrhosis. Scand J Gastroenterol 2022;:1-9. [PMID: 35514215 DOI: 10.1080/00365521.2022.2065889] [Reference Citation Analysis]
130 Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, Marasco G, Taddia M, Lisotti A, Mazzella G, Di Biase AR, Golfieri R, Pinzani M, Festi D. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol. 2014;60:1158-1164. [PMID: 24607624 DOI: 10.1016/j.jhep.2014.02.024] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
131 Etzion O, Takyar V, Novack V, Gharib AM, Canales R, Adebogun A, Matsumoto E, Eccleston JL, Kleiner DE, Rosenzweig SD, Gunay-Aygun M, Uzel G, Fuss I, Childs R, Holland SM, Levy EB, Liang TJ, Heller T, Koh C. Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension. Hepatol Commun 2018;2:919-28. [PMID: 30094403 DOI: 10.1002/hep4.1198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
132 Bassegoda O, Olivas P, Turco L, Mandorfer M, Serra-Burriel M, Tellez L, Kwanten W, Laroyenne A, Farcau O, Alvarado E, Moga L, Vuille-Lessard E, Fortea JI, Ibañez L, Tosetti G, Vanwolleghem T, Larrue H, Burgos-Santamaría D, Stefanescu H, Paternostro R, Cippitelli A, Lens S, Augustin S, Llop E, Laleman W, Trebicka J, Chang J, Masnou H, Zipprich A, Miceli F, Semmler G, Forns X, Primignani M, Bañares R, Puente A, Berzigotti A, Rautou PE, Villanueva C, Ginès P, Garcia-Pagan JC, Procopet B, Bureau C, Albillos A, Francque S, Reiberger T, Schepis F, Graupera I, Hernandez-Gea V. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01136-8. [PMID: 34688952 DOI: 10.1016/j.cgh.2021.10.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Kim TY, Suk KT, Jeong SW, Ryu T, Kim DJ, Baik SK, Sohn JH, Jeong WK, Choi E, Jang JY, Kim MY. The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients. J Korean Med Sci 2019;34:e223. [PMID: 31436052 DOI: 10.3346/jkms.2019.34.e223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Chen SH, Wan QS, Wang T, Zhang KH. Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis. Biomed Res Int 2020;2020:7170457. [PMID: 32280697 DOI: 10.1155/2020/7170457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-438 [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 14.2] [Reference Citation Analysis]
136 Talal AH, Venuto CS, Younis I. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. Clin Pharmacol Drug Dev 2017;6:206-12. [PMID: 28263464 DOI: 10.1002/cpdd.336] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
137 Bedossa P, Garcia-Tsao G, Jain D. Cirrhosis Regression and Subclassification. Surg Pathol Clin 2013;6:295-309. [PMID: 26838976 DOI: 10.1016/j.path.2013.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
138 Bloom S, Kemp W, Lubel J. Portal hypertension: pathophysiology, diagnosis and management: Portal hypertension current concepts. Intern Med J 2015;45:16-26. [DOI: 10.1111/imj.12590] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 5.9] [Reference Citation Analysis]
139 Hobolth L, Bendtsen F, Møller S. Indications for portal pressure measurement in chronic liver disease. Scandinavian Journal of Gastroenterology 2012;47:887-92. [DOI: 10.3109/00365521.2012.706827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
140 Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf)5:113-126. [PMID: 28533909 DOI: 10.1093/gastro/gox007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
141 Masood I, Saleem A, Malik K, Rashidi L, Kathuria M. TIPS to the rescue: Preoperative Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement in a patient with caput medusae and colon cancer. Radiol Case Rep 2020;15:1423-7. [PMID: 32642010 DOI: 10.1016/j.radcr.2020.06.023] [Reference Citation Analysis]
142 Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int 2021;41:1734-43. [PMID: 34051060 DOI: 10.1111/liv.14977] [Reference Citation Analysis]
143 Erice E, Llop E, Berzigotti A, Abraldes JG, Conget I, Seijo S, Reverter E, Albillos A, Bosch J, García-Pagán JC. Insulin resistance in patients with cirrhosis and portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1458-G1465. [PMID: 22492691 DOI: 10.1152/ajpgi.00389.2011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
144 Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology. 2013;85:153-159. [PMID: 23988857 DOI: 10.1159/000354416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
145 Wang T, Liang F, Zhou Z, Qi X. Global sensitivity analysis of hepatic venous pressure gradient (HVPG) measurement with a stochastic computational model of the hepatic circulation. Computers in Biology and Medicine 2018;97:124-36. [DOI: 10.1016/j.compbiomed.2018.04.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
146 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
147 Gui H, Huang Y, Zhao G, Chen L, Cai W, Wang H, Guo Q, Xie Q. External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy. Front Med (Lausanne) 2021;8:677920. [PMID: 34422855 DOI: 10.3389/fmed.2021.677920] [Reference Citation Analysis]
148 Ikenaga N, Liu SB, Sverdlov DY, Yoshida S, Nasser I, Ke Q, Kang PM, Popov Y. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 2015;185:325-34. [PMID: 25478810 DOI: 10.1016/j.ajpath.2014.10.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
149 Ravaioli F, Montagnani M, Lisotti A, Festi D, Mazzella G, Azzaroli F. Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. Gastroenterol Res Pract 2018;2018:4202091. [PMID: 29977287 DOI: 10.1155/2018/4202091] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
150 Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Invest. 2019;49:e13056. [PMID: 30474209 DOI: 10.1111/eci.13056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
151 Mohamed AA, Elsaid OM, Amer EA, Elosaily HH, Sleem MI, Gerges SS, Saleh MA, El Shimy A, El Abd YS. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 2017;8:343-9. [PMID: 28417047 DOI: 10.1016/j.jare.2017.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
152 Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver Int 2016;36:1649-56. [PMID: 27169985 DOI: 10.1111/liv.13160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
153 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
154 Groszmann RJ. Buenos Aires to New Haven: A dream trip. Hepatology 2010;52:1-9. [DOI: 10.1002/hep.23643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
156 Ryu SR, Yoo JJ, Kang SH, Jeong SW, Kim MY, Cho YK, Chang Y, Kim SG, Jang JY, Kim YS, Baik SK, Kim YJ, Park SY, Baymbajav B. The cut-off value of transient elastography to the value of hepatic venous pressure gradient in alcoholic cirrhosis. Clin Mol Hepatol 2021;27:197-206. [PMID: 33317252 DOI: 10.3350/cmh.2020.0171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Tsai M, Chen C, Hu T, Lu S, Lee C, Wang J, Hung C. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. Journal of the Formosan Medical Association 2017;116:512-21. [DOI: 10.1016/j.jfma.2016.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
158 Cagnin M, Biasiolo A, Martini A, Ruvoletto M, Quarta S, Fasolato S, Angeli P, Fassina G, Pontisso P. Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Sci Rep 2019;9:20126. [PMID: 31882893 DOI: 10.1038/s41598-019-56633-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Diaz-Sanchez A, Matilla A, Nuñez O, Lorente R, Fernandez A, Rincón D, Campos R, Bañares R, Clemente G. Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastroenterol 2013;48:334-43. [PMID: 23249262 DOI: 10.3109/00365521.2012.746391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
160 Cunningham ME, Parastandeh-Chehr G, Cerocchi O, Wong DK, Patel K. Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension. Can J Gastroenterol Hepatol 2019;2019:1808797. [PMID: 30881946 DOI: 10.1155/2019/1808797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
161 Rincón D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, Salcedo M, Matilla A, Senosiain M, Clemente G. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol. 2013;48:487-495. [PMID: 22871085 DOI: 10.3109/00365521.2012.711848] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
162 Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology. 2010;51:1894-1896. [PMID: 20512984 DOI: 10.1002/hep.23710] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
163 Lens S, Berbel C, Forns X, García-pagán JC. Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction? Curr Hepatology Rep 2018;17:209-17. [DOI: 10.1007/s11901-018-0405-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 D'ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? Liver Int 2016;36:783-90. [DOI: 10.1111/liv.13106] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
165 Uschner FE, Schueller F, Nikolova I, Klein S, Schierwagen R, Magdaleno F, Gröschl S, Loosen S, Ritz T, Roderburg C, Vucur M, Kristiansen G, Lammers T, Luedde T, Trebicka J. The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. Oncotarget 2018;9:36220-37. [PMID: 30546838 DOI: 10.18632/oncotarget.26333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
166 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
167 Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol J 2019;7:850-8. [PMID: 31316789 DOI: 10.1177/2050640619840199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
168 Kitson MT, Roberts SK, Colman JC, Paul E, Button P, Kemp W. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scandinavian Journal of Gastroenterology 2015;50:462-9. [DOI: 10.3109/00365521.2014.964758] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
169 Dajti E, Alemanni LV, Marasco G, Montagnani M, Azzaroli F. Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests? Hepat Med 2021;13:25-36. [PMID: 33776492 DOI: 10.2147/HMER.S278077] [Reference Citation Analysis]
170 Baiges A, Hernández-Gea V, Bosch J. Pharmacologic prevention of variceal bleeding and rebleeding. Hepatol Int 2018;12:68-80. [PMID: 29210030 DOI: 10.1007/s12072-017-9833-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
171 Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15:308. [PMID: 23314828 DOI: 10.1007/11894-0.12-0308-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M, Festi D. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. Journal of Hepatology 2019;70:440-8. [DOI: 10.1016/j.jhep.2018.10.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
173 Singal AK, Ahmad M, Soloway RD. Duplex Doppler ultrasound examination of the portal venous system: an emerging novel technique for the estimation of portal vein pressure. Dig Dis Sci. 2010;55:1230-1240. [PMID: 19629688 DOI: 10.1007/s10620-009-0887-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
174 Mukund A, Rana S, Mohan C, Kalra N, Baijal SS. Indian College of Radiology and Imaging Evidence-Based Guidelines for Interventions in Portal Hypertension and Its Complications. Indian J Radiol Imaging. [DOI: 10.1055/s-0041-1740235] [Reference Citation Analysis]
175 Mura VL, Nicolini A, Tosetti G, Primignani M. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol 2015; 7(4): 688-695 [PMID: 25866605 DOI: 10.4254/wjh.v7.i4.688] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
176 Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41:415-21. [PMID: 25023358 DOI: 10.1053/j.seminoncol.2014.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
177 Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sánchez-Ruano JJ, Artaza-Varasa T, Saura-Montalban J, Ryan P, Resino S. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One 2017;12:e0184404. [PMID: 28880930 DOI: 10.1371/journal.pone.0184404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
178 Kim SU, Oh HJ, Wanless IR, Lee S, Han KH, Park YN. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol. 2012;57:556-563. [PMID: 22617153 DOI: 10.1016/j.jhep.2012.04.029] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 8.4] [Reference Citation Analysis]
179 Vorobioff JD, Groszmann RJ. Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage. Annals of Hepatology 2013;12:22-9. [DOI: 10.1016/s1665-2681(19)31381-x] [Cited by in Crossref: 12] [Article Influence: 1.3] [Reference Citation Analysis]
180 Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445-1449. [PMID: 20077563 DOI: 10.1002/hep.23478] [Cited by in Crossref: 319] [Cited by in F6Publishing: 291] [Article Influence: 26.6] [Reference Citation Analysis]
181 Faitot F, Allard MA, Pittau G, Ciacio O, Adam R, Castaing D, Cunha AS, Pelletier G, Cherqui D, Samuel D, Vibert E. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. Hepatology 2015;62:179-87. [PMID: 25914217 DOI: 10.1002/hep.27864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
182 Soresi M, Terranova A, Licata A, Serruto A, Montalto G, Brancatelli G, Giannitrapani L. Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. Biomed Res Int 2017;2017:4932759. [PMID: 28638828 DOI: 10.1155/2017/4932759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
183 Lens S, Alvarado-tapias E, Mariño Z, Londoño M, Llop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-gea V, Bosch J, Villanueva C, Forns X, García-pagán JC. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology 2017;153:1273-1283.e1. [DOI: 10.1053/j.gastro.2017.07.016] [Cited by in Crossref: 147] [Cited by in F6Publishing: 123] [Article Influence: 29.4] [Reference Citation Analysis]
184 Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abraldes JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clin Gastroenterol Hepatol 2015;13:1846-1853.e1. [PMID: 25912838 DOI: 10.1016/j.cgh.2015.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
185 Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schöfl R, Ziachehabi A, Maieron A. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test. PLoS One. 2016;11:e0149230. [PMID: 26895398 DOI: 10.1371/journal.pone.0149230] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
186 Qi XS, Bao YX, Bai M, Xu WD, Dai JN, Guo XZ. Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis. World J Gastroenterol 2015;21:3100-8. [PMID: 25780311 DOI: 10.3748/wjg.v21.i10.3100] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
187 Palaniyappan N, Cox E, Bradley C, Scott R, Austin A, O'Neill R, Ramjas G, Travis S, White H, Singh R, Thurley P, Guha IN, Francis S, Aithal GP. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol. 2016;65:1131-1139. [PMID: 27475617 DOI: 10.1016/j.jhep.2016.07.021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
188 Lisotti A, Azzaroli F, Cucchetti A, Buonfiglioli F, Cecinato P, Calvanese C, Simoni P, Arena R, Montagnani M, Golfieri R, Colecchia A, Festi D, Mazzella G. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. Liver Int. 2016;36:1313-1321. [PMID: 26786880 DOI: 10.1111/liv.13070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
189 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
190 Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. J Clin Gastroenterol 2020;54:503-11. [PMID: 32195771 DOI: 10.1097/MCG.0000000000001338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
192 Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-82. [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149] [Cited by in Crossref: 363] [Cited by in F6Publishing: 316] [Article Influence: 27.9] [Reference Citation Analysis]
193 Cui PJ, Yao J, Zhu Y, Zhang ZY, Yang J. Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension. Gastroenterol Res Pract 2017;2017:3943210. [PMID: 28855918 DOI: 10.1155/2017/3943210] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Suk KT. Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol. 2014;20:6-14. [PMID: 24757653 DOI: 10.3350/cmh.2014. 20.1.6] [Reference Citation Analysis]
195 Yeh WS, Yang SC, Liang CM, Li YC, Tai WC, Lee CH, Yang YH, Hsu CN, Tsai TH, Chuah SK, Wu CK. The Role of Non-Selective β-Blockers in Compensated Cirrhotic Patients without Major Complications. Medicina (Kaunas) 2019;56:E14. [PMID: 31905956 DOI: 10.3390/medicina56010014] [Reference Citation Analysis]
196 Li P, Wu L, Li Z, Li J, Ye W, Shi Z, Xu Z, Zhu C, Ye H, Liu Z, Liang C. Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection. Front Oncol 2021;11:716849. [PMID: 34485152 DOI: 10.3389/fonc.2021.716849] [Reference Citation Analysis]
197 Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: A meta-analysis of randomized trials. Liver Int. 2015;35:2009-2016. [PMID: 25581713 DOI: 10.1111/liv.12782] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
198 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]
199 D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563-576. [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 23.2] [Reference Citation Analysis]
200 Suk KT, Kim EJ, Kim DJ, Kim HS, Bang CS, Park TY, Baik GH, Kim SE, Park JW, Park SH, Lee MS, Kim HS, Jang MK, Park SH, Choi E, Kim CH, Sung H, Park CK. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma. J Clin Gastroenterol 2017;51:285-93. [PMID: 27661973 DOI: 10.1097/MCG.0000000000000671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
201 Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation. Hepatology. 2015;61:375-381. [PMID: 24913395 DOI: 10.1002/hep.27249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
202 Sartor C, Bachelot L, Godard C, Lager F, Renault G, Gonzalez FJ, Perret C, Gougelet A, Colnot S. The concomitant loss of APC and HNF4α in adult hepatocytes does not contribute to hepatocarcinogenesis driven by β-catenin activation. Liver Int 2019;39:727-39. [PMID: 30721564 DOI: 10.1111/liv.14068] [Reference Citation Analysis]
203 Zhang ZB, Shi Z, Yang LF, Gao HB. Caveolin-1 Knockdown Decreases SMMC7721 Human Hepatocellular Carcinoma Cell Invasiveness by Inhibiting Vascular Endothelial Growth Factor-Induced Angiogenesis. Can J Gastroenterol Hepatol 2020;2020:8880888. [PMID: 32676485 DOI: 10.1155/2020/8880888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56:696-703. [PMID: 21767510 DOI: 10.1016/j.jhep.2011.07.005] [Cited by in Crossref: 215] [Cited by in F6Publishing: 175] [Article Influence: 19.5] [Reference Citation Analysis]
205 Marozas M, Zykus R, Sakalauskas A, Kupčinskas L, Lukoševičius A. Noninvasive Evaluation of Portal Hypertension Using a Supervised Learning Technique. J Healthc Eng 2017;2017:6183714. [PMID: 29158886 DOI: 10.1155/2017/6183714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
206 Takeishi K, Kawanaka H, Itoh S, Harimoto N, Ikegami T, Yoshizumi T, Shirabe K, Maehara Y. Impact of Splenic Volume and Splenectomy on Prognosis of Hepatocellular Carcinoma Within Milan Criteria After Curative Hepatectomy. World J Surg 2018;42:1120-8. [PMID: 28920178 DOI: 10.1007/s00268-017-4232-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
207 Sung K, Johnston MP, Lee MY, Byrne CD. Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. Liver Int 2020;40:1303-15. [DOI: 10.1111/liv.14416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
208 Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatol Int. 2018;12:1-10. [PMID: 29064029 DOI: 10.1007/s12072-017-9827-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
209 Koch DG, Bogatkevich G, Ramshesh V, Lemasters JJ, Uflacker R, Reuben A. Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci. 2012;57:516-523. [PMID: 21964742 DOI: 10.1007/s10620-011-1905-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
210 Kennedy P, Bane O, Hectors SJ, Fischman A, Schiano T, Lewis S, Taouli B. Noninvasive imaging assessment of portal hypertension. Abdom Radiol 2020;45:3473-95. [DOI: 10.1007/s00261-020-02729-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
211 Sharma P. Value of Liver Function Tests in Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.11.004] [Reference Citation Analysis]
212 Krag A, Roskams T, Pinzani M, Mueller S. Diagnostic challenges in patients with alcohol-related liver disease. Z Gastroenterol 2022;60:45-57. [PMID: 35042253 DOI: 10.1055/a-1713-4372] [Reference Citation Analysis]
213 Suk KT. Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol. 2014;20:6-14. [PMID: 24757653 DOI: 10.3350/cmh.2014.20.1.6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
214 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 25.0] [Reference Citation Analysis]
215 Cohen EB, Afdhal NH. Ultrasound-based hepatic elastography: origins, limitations, and applications. J Clin Gastroenterol. 2010;44:637-645. [PMID: 20844365 DOI: 10.1097/mcg.0b013e3181e12c39] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]